Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT05369234Phase 3Completed
Phase 3, randomised, single-blind trial (4 cohorts), sponsored by Thompson Cancer Survival Center. Primary endpoints: Prevention of Oral Mucositis and Esophagitis at 10 weeks and Management of Oral Mucositis and Esophagitis at 10 weeks. Started Jan 2022; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT05369234.